Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retifanlimab in Advanced Merkel Cell Carcinoma
NCT03599713Phase 2Completed
- Sponsor
- Incyte
- Start
- Feb 2019
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of retifanlimab in Merkel cell carcinoma (MCC), sponsored by Incyte. Started Feb 2019; status: completed.
02
Drugs
retifanlimab
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT03599713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03599713.